Merck Loses Chance For Primary Care Blockbuster With Odanacatib Failure
Termination of osteoporosis drug odanacatib due to stroke risk means a loss for Merck in reliving the glory days of branded Fosamax.
You may also be interested in...
The latest drug development news and highlights from our FDA Performance Tracker.
Abaloparatide looks better for improving bone mass with less hypercalcemia than Lilly's first-in-class Forteo in the Phase III ACTIVE study, but it remains to be seen whether this will be enough to get ahead in the increasingly crowded osteoporosis market.
Amgen Inc. and partner UCB Group have filed their osteoporosis drug romosozumab, which is anticipated to drive sales of more than $700m worldwide by 2023, in the US for the treatment of postmenopausal women at risk of fractures.